Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, on what date NHS England informed patients receiving the Oxford-AstraZeneca Covid-19 vaccine that there were safety risks of vaccine-induced thrombosis with thrombocytopenia associated with the vaccine.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps NHS England took to ensure that informed consent was given by recipients of the Oxford-AstraZeneca covid-19 vaccine.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether (a) his Department and (b) the Medicines and Healthcare products Regulatory Agency has received data from Astra Zeneca on the potential serious adverse effects of its covid-19 vaccine for a small number of recipients.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Department has not directly received data from AstraZeneca regarding potential adverse effects of their COVID-19 vaccine Vaxzevria, as it is not the appropriate body to receive this information. It instead relies on the expert advice of the Medicines and Healthcare products Regulatory Agency (MHRA).
All vaccine manufacturers have a legal responsibility to mitigate risk and monitor the safety and performance of vaccines throughout the product lifecycle. This includes a legal responsibility to transmit reports of suspected adverse reactions received directly to the MHRA. Following the MHRA’s receipt of the first Yellow Card reports of suspected thrombosis and associated thrombocytopaenia associated with the Vaxzevria vaccine in February 2021, AstraZeneca provided the Commission on Human Medicines’ Vaccine Benefit Risk Expert Working Group an analysis of the age stratified risk of thrombosis with thrombocytopenia associated with the AstraZeneca vaccine. This was assessed by the Commission on Human Medicines, with the Patient Information updated to state the risks of these events.
May. 08 2024
Source Page: Community Life Survey: October to December 2023 quarterly releaseFound: Helping someone who is self -isolating due to coronavirus © Kantar Public 2021 35 12.
Asked by: Gavin Williamson (Conservative - South Staffordshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help increase the provision of covid-19 booster vaccinations to community pharmacies.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
Community pharmacies have been taking part in the COVID-19 vaccination programme since January 2021. NHS England has recently changed the model for procuring COVID-19 vaccination services to an opt-in model. All community pharmacies who applied, and met the minimum requirements, received a contract to deliver COVID-19 vaccinations. This enabled more pharmacies to support the autumn 2023/24 booster campaign, administering COVID-19 vaccinations alongside flu vaccinations, which are also increasingly being administered in these settings.
May. 07 2024
Source Page: Communal accommodation settings: infectious disease transmissionFound: Ghinai I and others. ' Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in
Found: swiftly, providing support worth £373 billion to the economy during the pandemic, including through the Coronavirus
May. 02 2024
Source Page: Flu & COVID-19 Vaccination Programme (FVCV) 2023-24 Child Rights and Wellbeing Impact AssessmentFound: Flu & COVID-19 Vaccination Programme (FVCV) 2023-24 Child Rights and Wellbeing Impact Assessment
May. 02 2024
Source Page: Flu & COVID-19 Vaccination Programme (FVCV) 2023-24 Equality Impact AssessmentFound: Flu & COVID-19 Vaccination Programme (FVCV) 2023-24 Equality Impact Assessment
Laid - 29 Apr 2024 In Force Not stated
Regulation 2 amends regulation 24 of the National Health Service (Performers Lists) (England) Regulations 2013 (S.I. 2013/335), which provided exemptions to the requirement that a medical practitioner must be a general medical practitioner included in the medical performers list in order to perform primary medical services. It amends the exemption …
Found: The following are revoked— (a)the National Health Service (Performers Lists) (England) (Coronavirus)